Your browser doesn't support javascript.
loading
Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature.
Leicht, Hans Benno; Weinig, Elke; Mayer, Beate; Viebahn, Johannes; Geier, Andreas; Rau, Monika.
Afiliación
  • Leicht HB; Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany.
  • Weinig E; Institute of Transfusion Medicine and Haemotherapy, University of Wuerzburg, Wuerzburg, Germany.
  • Mayer B; Institute of Transfusion Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Viebahn J; Institute of Transfusion Medicine and Haemotherapy, University of Wuerzburg, Wuerzburg, Germany.
  • Geier A; Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany.
  • Rau M; Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany. rau_m@ukw.de.
BMC Pharmacol Toxicol ; 19(1): 67, 2018 Oct 25.
Article en En | MEDLINE | ID: mdl-30359322
BACKGROUND: Drug induced immune hemolytic anemia (DIIHA) is a rare complication and often underdiagnosed. DIIHA is frequently associated with a bad outcome, including organ failure and even death. For the last decades, ceftriaxone has been one of the most common drugs causing DIIHA, and ceftriaxone-induced immune hemolytic anemia (IHA) has especially been reported to cause severe complications and fatal outcomes. CASE PRESENTATION: A 76-year-old male patient was treated with ceftriaxone for cholangitis. Short time after antibiotic exposure the patient was referred to intensive care unit due to cardiopulmonary instability. Hemolysis was observed on laboratory testing and the patient developed severe renal failure with a need for hemodialysis for 2 weeks. Medical history revealed that the patient had been previously exposed to ceftriaxone less than 3 weeks before with subsequent hemolytic reaction. Further causes for hemolytic anemia were excluded and drug-induced immune hemolytic (DIIHA) anemia to ceftriaxone could be confirmed. CONCLUSIONS: The case demonstrates the severity of ceftriaxone-induced immune hemolytic anemia, a rare, but immediately life-threatening condition of a frequently used antibiotic in clinical practice. Early and correct diagnosis of DIIHA is crucial, as immediate withdrawal of the causative drug is essential for the patient prognosis. Thus, awareness for this complication must be raised among treating physicians.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ceftriaxona / Insuficiencia Renal / Anemia Hemolítica / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: BMC Pharmacol Toxicol Año: 2018 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ceftriaxona / Insuficiencia Renal / Anemia Hemolítica / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: BMC Pharmacol Toxicol Año: 2018 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido